US OptionsDetailed Quotes
UBER241213C90000
- 0.01
- 0.000.00%
15min DelayClose Dec 13 16:00 ET
0.01High0.01Low
0.01Open0.01Pre Close5 Volume20 Open Interest90.00Strike Price5.00Turnover5545.18%IV50.19%PremiumDec 13, 2024Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry0.01Extrinsic Value100Contract SizeAmericanOptions Type0.0038Delta0.0013Gamma5993.00Leverage Ratio-16.2370Theta0.0000Rho22.80Eff Leverage0.0000Vega
Uber Technologies Stock Discussion
Sign in to post a comment
$Esperion Therapeutics (ESPR.US)$ $Esperion Therapeutics (ESPR.US)$ Esperion Therapeutics (ESPR) is a biotech company that focuses on developing and commercializing therapies to lower cholesterol, specifically offering the only FDA-approved statin alternatives: NEXLIZET and NEXLETOL for PRIMARY PREVENTION. These drugs are designed for individuals who are statin intolerant or cannot achieve adequate cholesterol lowering with statin...
+4
1
6
This unique biotech $Esperion Therapeutics (ESPR.US)$ Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, Statins are a class of prescription drugs that help lower cholesterol levels. They are the most common treatment for high cholesterol, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 ...
+2
9
1
4
$Uber Technologies (UBER.US)$ robotaxi will kill Uber
1
1
$Uber Technologies (UBER.US)$ how can this stock get any lower?!
1
1
$Uber Technologies (UBER.US)$ bankruptcy
1
1
$Uber Technologies (UBER.US)$ and Adobe, beat the estimates but no bright future? ugh
1
2
$Uber Technologies (UBER.US)$ the laughing stock of the stock market
$Uber Technologies (UBER.US)$ this stock is donezo. tesla and waymo will eat all of its demand up. best short target
No comment yet
Millaai : Are you being trapped and looking for a rescuer everywhere?
Growth Investor27 : Good info, NEXLIZET is a great drug, my brother takes it. ESPR stock is undervalued, should be above $5
Growth Investor27 Millaai : The author has been buying below $2 so your comment is off. This research article has all the due diligence to see, other than the fact Institutions have been heavly buying this year, fintel shows now 74% owned. ESPR is a good investment.
104248191 : please f o
Detached House Millaai : You are wrong. Though short term looks like the price is consolidating, the weekly chart looks promising! So look at the chart to see if it aligns with the fundamentals before criticising others!
View more comments...